Advice
following an abbreviated submission:
emtricitabine/tenofovir alafenamide (Descovy®) is accepted for use within NHS Scotland.
Indication under review: in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35kg) infected with human immunodeficiency virus type 1.
For adult patients in whom emtricitabine/tenofovir is an appropriate combination, Descovy® (emtricitabine/tenofovir alafenamide) offers an alternative to Truvada® (emtricitabine/ tenofovir disoproxil) at no additional cost, and may also be used in patients from 12 years of age.
Download detailed advice111KB (PDF)
Medicine details
- Medicine name:
- emtricitabine/tenofovir alafenamide (Descovy)
- SMC ID:
- 1169/16
- Indication:
- In combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35kg) infected with human immunodeficiency virus type 1.
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Infections
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 08 August 2016